Evidence map›Paper›PMID 41975230›Full record

ReviewNature reviews. Cancer2026

Rethinking ovarian cancer III: the past decade and future directions.

Frances R Balkwill, Céline M Laumont, Nikki Burdett, Olivia Le Saux, Dale W Garsed, Whitney R Grither, Anke M Nijhuis, Maria S Recouvreux, Ziqi Kang, Rugang Zhang and 28 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Frances R BalkwillBarts Cancer Institute, Queen Mary University of London, London, UK. F.balkwill@qmul.ac.uk.ORCID http://orcid.org/0000-0002-5587-9759
Céline M LaumontDeeley Research Centre, BC Cancer Victoria, Victoria, British Columbia, Canada.ORCID http://orcid.org/0000-0002-9067-4054
Nikki BurdettPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Olivia Le SauxCentre Léon Bérard, Lyon, France.
Dale W GarsedPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-1223-0121
Whitney R GritherWashington University in St. Louis, Saint Louis, MO, USA.
Anke M NijhuisImperial College London, London, UK.
Maria S RecouvreuxUniversity of California, Los Angeles, Los Angeles, CA, USA.
Ziqi KangUniversity of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID http://orcid.org/0009-0003-2084-610X
Rugang ZhangUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7255-2360
Katherine B ChiappinelliGeorge Washington University, Washington, DC, USA.
Jason S LeeFrazer Institute, The University of Queensland, Woolloongabba, Queensland, Australia.ORCID http://orcid.org/0000-0003-0879-934X
Denarda Dangaj LanitiLausanne University Hospital and Lausanne Branch of the Ludwig Institute for Cancer Research, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-5659-6427
Iain McNeishImperial College London, London, UK.ORCID http://orcid.org/0000-0002-9387-7586
Ahmed A AhmedMRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-6509-2581
Robert RottapelPrincess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Jose R Conejo-GarciaDuke University School of Medicine, Durham, NC, USA.ORCID http://orcid.org/0000-0001-6431-4074
Kunle OdunsiUniversity of Chicago, Chicago, IL, USA.
Paul D P PharoahCedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-8494-732X
Dmitriy ZamarinIcahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-0094-0161
Charles A IshakUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christina FotopoulouDepartment of Surgery and Cancer, Faculty of Medicine of Imperial College London, London, UK.
Ronald J BuckanovichMagee Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Intidhar Labidi-GalyUniversité de Genève and Hôpitaux Universitaires de Genève, Geneva, Switzerland.
James D BrentonCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-5738-6683
Ernst LengyelUniversity of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0001-8624-1507
David P CookOttawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Sophia H L GeorgeSylvester Comprehensive Cancer Center University of Miami Miller School of Medicine, Miami, FL, USA.ORCID http://orcid.org/0000-0003-1013-1883
Stephanie LheureuxPrincess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Ronny DrapkinUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-6912-6977
Kenneth P NephewIndiana University School of Medicine, Bloomington, IN, USA.
Sarah AdamsUniversity of New Mexico Comprehensive Cancer Centre, Albuquerque, NM, USA.ORCID http://orcid.org/0000-0002-0240-1380
Shailja PathaniaUniversity of Massachusetts, Boston, MA, USA.
Brad H NelsonDeeley Research Centre, BC Cancer Victoria, Victoria, British Columbia, Canada.ORCID http://orcid.org/0000-0002-4445-5539
Anniina FärkkiläUniversity of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Katherine FuhUniversity of California, San Francisco, San Francisco, CA, USA.
Benjamin G NeelNYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-9589-585X
David D BowtellPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia. David.bowtell@petermac.org.

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3M
NCI NIH HHS P30 CA082709
6 · The paper itself

Abstract

Approximately 80% of deaths from ovarian cancer are due to high-grade serous carcinoma (HGSC), which has the highest proportion of BRCA1 or BRCA2 (BRCA1/BRCA2) mutations of any cancer type and is a highly chromosomally unstable disease. Despite the introduction of targeted therapies benefitting some patients with HGSC as well as surgical advances, only 50% of patients will survive more than 5 years, and just 30% of patients who present with advanced disease without BRCA1/BRCA2 mutations will survive this long. This Expert Recommendation is based on discussions among emerging and leading ovarian cancer researchers at the 15th Helene Harris Memorial Trust International Forum on ovarian cancer hosted by Ovarian Cancer Action in October 2024. The meeting considered advances in HGSC research and treatment made over the last decade, current challenges, emerging technologies in prevention, early detection, and treatment, and research priorities for the years ahead.

Indexed as

Cystadenocarcinoma, SerousOvarian NeoplasmsBRCA1 ProteinBRCA2 ProteinFemaleHumansMutationBRCA1 ProteinBRCA2 Protein

Identifiers

PMID41975230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.